Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Other Accumulated Expenses (2022 - 2024)

Immunocore Holdings' Other Accumulated Expenses history spans 3 years, with the latest figure at $7.5 million for Q1 2024.

  • For Q1 2024, Other Accumulated Expenses changed N/A year-over-year to $7.5 million; the TTM value through Mar 2024 reached $7.5 million, changed N/A, while the annual FY2023 figure was $6.0 million, 62.74% up from the prior year.
  • Other Accumulated Expenses for Q1 2024 was $7.5 million at Immunocore Holdings, up from $6.0 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $7.5 million in Q1 2024 and bottomed at $3.7 million in Q4 2022.
  • The 3-year median for Other Accumulated Expenses is $6.0 million (2023), against an average of $5.7 million.
  • The largest YoY upside for Other Accumulated Expenses was 62.74% in 2023 against a maximum downside of 62.74% in 2023.
  • A 3-year view of Other Accumulated Expenses shows it stood at $3.7 million in 2022, then skyrocketed by 62.74% to $6.0 million in 2023, then grew by 24.49% to $7.5 million in 2024.
  • Per Business Quant, the three most recent readings for IMCR's Other Accumulated Expenses are $7.5 million (Q1 2024), $6.0 million (Q4 2023), and $3.7 million (Q4 2022).